Metraipolis › archive › dc_c425486a0963

OATP1B3 c.699G>A Predicts a 6.3-Fold Increased Risk of Hyperbilirubinemia During OPrD Therapy for HCV — Europe PMC PMID:42193057

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42193057
DOI
10.3390/cimb48050452
License (as archived)
solo-consultazione
Archived
2026-11-03T04:30:21.501Z
SHA-256 of the archived text
48807b68b474844a43b08957fbcf0bf8d1d8859049a5a15c9e86c66b6ed18538
Stable URL of this page
https://metraipolis.com/documento/dc_c425486a0963

How to cite

OATP1B3 c.699G>A Predicts a 6.3-Fold Increased Risk of Hyperbilirubinemia During OPrD Therapy for HCV — Europe PMC PMID:42193057 — Europe PMC (en), https://europepmc.org/article/MED/42193057 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c425486a0963 (Metraipolis archive dc_c425486a0963, sha256 48807b68b474844a43b08957fbcf0bf8d1d8859049a5a15c9e86c66b6ed18538)
BibTeX
@misc{dcc425486a0963,
  title = {OATP1B3 c.699G>A Predicts a 6.3-Fold Increased Risk of Hyperbilirubinemia During OPrD Therapy for HCV — Europe PMC PMID:42193057},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42193057},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c425486a0963; sha256 48807b68b474844a43b08957fbcf0bf8d1d8859049a5a15c9e86c66b6ed18538},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42193057. Agents can read the archived copy with the MCP tool read_document.